Imatinib Zydus

Imatinib mesilate, the active ingredient in Imatinib Zydus, is a tyrosine kinase inhibitor presented as a tablet for oral use. It treats chronic myeloid leukemia and gastrointestinal stromal tumor in adult patients.

GNH USA supplies Imatinib Zydus as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Imatinib Zydus is a tyrosine kinase inhibitor used in malignancies driven by BCR‑ABL or KIT signaling pathways.

- Chronic Myeloid Leukemia (CML): reduces leukemic cell proliferation and improves long‑term survival. - Gastrointestinal Stromal Tumor (GIST): inhibits tumor growth and delays disease progression. - Philadelphia chromosome‑positive Acute Lymphoblastic Leukemia (Ph+ ALL): provides disease control in adult patients.

Imatinib may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea and vomiting - Edema, especially peripheral - Muscle cramps or pain - Fatigue or weakness - Diarrhea or abdominal discomfort - Skin rash or pruritus

Serious or Rare Side Effects: - Neutropenia or severe leukopenia - Hepatotoxicity with elevated transaminases - Cardiac failure or reduced left‑ventricular function - Pulmonary arterial hypertension - Severe skin reactions such as Stevens‑Johnson syndrome - Tumor lysis syndrome in high‑burden disease

Before initiating therapy, several safety considerations should be addressed.

- Monitor blood counts: perform regular CBC to detect cytopenias. - Assess liver function: check transaminases and bilirubin periodically. - Evaluate cardiac status: baseline and periodic echocardiograms for patients with cardiac risk. - Pregnancy and lactation: avoid use unless benefits outweigh potential fetal risks. - Dose adjustments: consider hepatic impairment when determining dose. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Imatinib interacts with several drug classes that can alter its exposure or increase toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): raise plasma concentrations. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): lower plasma concentrations. - Concomitant QT‑prolonging agents: increase risk of arrhythmia.

Moderate Interactions (Monitor Closely): - Antacids containing aluminum or magnesium: may reduce oral absorption. - Warfarin: may potentiate anticoagulant effect and raise INR. - CYP2C8 inhibitors (e.g., gemfibrozil): can increase imatinib levels.